Adriamycin

(Doxorubicin)

ApprovedSmall molecule

Doxorubicin is a chemotherapy drug used to treat various types of cancer by damaging cancer cells and stopping them from growing and dividing. It's commonly used for breast cancer, lymphomas, and leukemias.[2] Adriamycin is currently approved and in use across 121 indications[4].[1]

Adriamycin is one of 1209 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Approved.

121

Indications

681

Total Trials

Active Trials

1,208

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Acute Lymphoblastic LeukemiaCompleted

Triple-Negative Breast CancerRecruiting

Classic Hodgkin LymphomaActive, not recruiting

Diffuse Large B-Cell LymphomaTerminated

Soft Tissue SarcomaRecruiting

LeiomyosarcomaCompleted

Diffuse Intrinsic Pontine GliomaTerminated

Bladder CancerTerminated

Solid TumorsRecruiting

LenalidomideUnknown status

Acute Lymphoblastic LeukemiaApproved

Completed

Triple-Negative Breast CancerPhase 2

Recruiting

Classic Hodgkin LymphomaPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Terminated

Soft Tissue SarcomaPhase 3

Recruiting

LeiomyosarcomaPhase 3

Completed

Diffuse Intrinsic Pontine GliomaPhase 2

Terminated

Bladder CancerPhase 3

Terminated

Solid TumorsPhase 1

Recruiting

LenalidomidePhase 2

Unknown status

Showing 10 of 120 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Approved

119 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 4

Duragesic

CCephalon

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Tricor

JJagotec

Preclinical

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Breast Cancer

NCT04083963

Phase 1Active, not recruiting

Other Solid Tumors

NCT00479128

Q4 2026

Phase 2Recruiting

Immunotherapy

NCT05645380

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT05785754

Phase 2/3Active, not recruiting

Soft Tissue Sarcoma

NCT02180867

Phase 2Recruiting

Blinatumomab

NCT06250959

Clinical

Trials by Indication[1]

Breast Cancer38 trials

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06404463·76 enrolled

Molecular Triaging of Newly Diagnosed Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·N/A·NCT01159236

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Active, not recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT04083963·13 enrolled

Show 35 more trials

Docetaxel in Node Positive Adjuvant Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00688740·1,491 enrolled

A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00102219·77 enrolled

TAC Versus TC for Adjuvant Breast Cancer

Completed·UUS Oncology Research·Phase 3·NCT00493870·1,961 enrolled

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Completed·NNSABP Foundation Inc·Phase 3·NCT00002707·2,411 enrolled

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Completed·—·Phase 2·NCT00546156·104 enrolled

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT00580333·51 enrolled

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Completed·—·Phase 2·NCT00146562·135 enrolled

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Terminated· GSK logo

GSK·Phase 2·NCT01220128·66 enrolled

A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel

Completed·—··NCT00131963·94 enrolled

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00789581·614 enrolled

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Unknown status·RRussian Academy of Medical Sciences·Phase 2·NCT02685657·164 enrolled

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT03329378·7 enrolled

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Completed·NNSABP Foundation Inc·Phase 3·NCT00887536·1,613 enrolled

Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer

Completed·HHospital San Carlos, Madrid·Phase 2·NCT00123929·250 enrolled

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01966471·1,846 enrolled

Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

Terminated·—·Phase 2·NCT02472353·30 enrolled

Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Unknown status·—··NCT00820690·80 enrolled

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting·BBaylor Breast Care Center·Phase 2·NCT05020860·185 enrolled

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Completed·—·Phase 1·NCT00976131·7 enrolled

Preoperative Herceptin and Navelbine for Breast Cancer

Completed·—·Phase 2·NCT00148681·49 enrolled

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 3·NCT02032277·634 enrolled

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03493854·500 enrolled

Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

Terminated·UUniversity of Utah·Phase 1·NCT01090128·27 enrolled

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Unknown status·AAiping Shi·Phase 2·NCT05088057·30 enrolled

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01593020·54 enrolled

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT03497702·114 enrolled

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Active, not recruiting·NNational University Hospital, Singapore·Phase 1/2·NCT05275777·66 enrolled

Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients

Completed·UUniversity of Campinas, Brazil·N/A·NCT03000036·27 enrolled

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Completed·GG1 Therapeutics, Inc.·Phase 2·NCT05112536·24 enrolled

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT02132949·401 enrolled

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT03725059·1,240 enrolled

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02215876

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Active, not recruiting·FFondazione Michelangelo·Phase 3·NCT03595592·650 enrolled

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Terminated·WWashington University School of Medicine·Phase 2·NCT01779050·7 enrolled

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated·HHoosier Cancer Research Network··NCT00235235·80 enrolled

Lymphoma34 trials

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00825149·137 enrolled

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Terminated·—·Phase 2·NCT00126191·10 enrolled

PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Terminated·UUniversity of Cologne·Phase 2·NCT00512980

Show 31 more trials

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054665·50 enrolled

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Recruiting·AAIDS Malignancy Consortium·Phase 1·NCT04139304·15 enrolled

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Unknown status·PPeking University·Phase 3·NCT03952572·244 enrolled

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT00324467·150 enrolled

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01719835·87 enrolled

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00787527·14 enrolled

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Unknown status·—·Phase 2·NCT06201507·44 enrolled

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

Completed·PPolish Lymphoma Research Group·Phase 3·NCT00801281·250 enrolled

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01974440·403 enrolled

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Unknown status·WWenqi Jiang·Phase 3·NCT02428751·216 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Terminated· Bayer logo

Bayer·Phase 3·NCT02626455·551 enrolled

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Terminated·SSun Yat-sen University·Phase 3·NCT02359162·50 enrolled

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT04914741·80 enrolled

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06630091·30 enrolled

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT01992653·85 enrolled

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677141·117 enrolled

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT03864419·18 enrolled

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT07097363·18 enrolled

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Unknown status·HHunan Cancer Hospital·Phase 2·NCT02918747·100 enrolled

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00290498·67 enrolled

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Active, not recruiting· Takeda logo

Takeda·Phase 1/2·NCT02979522·59 enrolled

Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

Completed·UUniversity of Cologne·Phase 1/2·NCT00147875·60 enrolled

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003389·854 enrolled

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Not yet recruiting·—·Phase 1·NCT07278856·20 enrolled

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Recruiting·SState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia·Phase 3·NCT04638790·300 enrolled

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT04933617·8 enrolled

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·N/A·NCT00651755·23 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00118209·524 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

Acute Lymphoblastic Leukemia12 trials

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00890656·90 enrolled

Treatment of Acute Lymphoblastic Leukemia in Children

Completed·—·Phase 3·NCT00165178·498 enrolled

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02419469·1 enrolled

Show 9 more trials

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Completed·MMassachusetts General Hospital·Phase 1·NCT02228772·19 enrolled

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109837·79 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Recruiting·TTanja Andrea Gruber·Phase 1·NCT04996160·22 enrolled

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00866749·120 enrolled

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

Completed·—·Phase 2·NCT00136435·100 enrolled

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01424982·88 enrolled

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Terminated·EEhab L Atallah·Phase 1·NCT01887587·5 enrolled

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT00440726·31 enrolled

Diffuse Large B-Cell Lymphoma11 trials

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting·PPatrick Reagan·Phase 2·NCT02734771·24 enrolled

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Terminated·LLymphoma Study Association·Phase 3·NCT00135499·138 enrolled

Show 8 more trials

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 1/2·NCT02951728·58 enrolled

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1/2·NCT07124936·97 enrolled

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

Withdrawn·AADC Therapeutics S.A.·Phase 1·NCT04974996

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Completed·LLund University Hospital·Phase 1/2·NCT01622439·50 enrolled

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT01040871·164 enrolled

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Completed·LLymphoma Study Association·Phase 2/3·NCT00169130·300 enrolled

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Completed· Takeda logo

Takeda·Phase 2·NCT00931918·206 enrolled

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449265·160 enrolled

Soft Tissue Sarcoma10 trials

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03283696·24 enrolled

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2/3·NCT02180867·140 enrolled

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

Unknown status·PPhilogen S.p.A.·Phase 2·NCT03420014·114 enrolled

Show 7 more trials

A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma

Completed·HHannover Medical School·Phase 2·NCT01861951·120 enrolled

A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00102609·41 enrolled

Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients

Recruiting·UUNICANCER·Phase 3·NCT04757337·214 enrolled

A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma

Completed· Roche logo

Roche·Phase 1·NCT01605526·23 enrolled

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02783599·51 enrolled

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Completed·TThreshold Pharmaceuticals·Phase 3·NCT01440088·640 enrolled

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Completed· Amgen logo

Amgen·Phase 1/2·NCT00626704·134 enrolled

59 more indications

Doxorubicin6 trials

Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS

Terminated·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT01104298·115 enrolled

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Completed·MMassachusetts General Hospital·Phase 1/2·NCT01027910·20 enrolled

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

Completed·—·Phase 2·NCT01670500·118 enrolled

Show 3 more trials

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Withdrawn·IImmune System Key Ltd·Phase 2·NCT03059615

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Not yet recruiting·ZZhejiang Teruisi Pharmaceutical Inc.·Phase 1/2·NCT07035379·66 enrolled

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Terminated·GGeorgetown University·Phase 1/2·NCT02261805·11 enrolled

Follicular Lymphoma5 trials

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06704555·20 enrolled

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Completed· GSK logo

GSK·Phase 2·NCT00494780·59 enrolled

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06284122·790 enrolled

Show 2 more trials

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06474481·30 enrolled

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Completed· Roche logo

Roche·Phase 3·NCT01889069·159 enrolled

Neuroblastoma4 trials

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT00808899·4 enrolled

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

Response-based Treatment of High-risk Neuroblastoma

Unknown status·SSamsung Medical Center·Phase 2·NCT02771743·54 enrolled

Show 1 more trial

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Mantle Cell Lymphoma4 trials

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02858804·55 enrolled

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00477412·107 enrolled

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00581776·30 enrolled

Show 1 more trial

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041132·56 enrolled

Liver Cancer4 trials

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown status·ZZhujiang Hospital·Phase 3·NCT05701436·144 enrolled

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown status·ZZhujiang Hospital·Phase 3·NCT05766605·90 enrolled

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

Completed·NNorthwestern University·Phase 2·NCT00956930·45 enrolled

Show 1 more trial

Study of Pegylated Human Recombinant Arginase for Liver Cancer

Completed·BBio-Cancer Treatment International Limited·Phase 1·NCT00988195·15 enrolled

Multiple Myeloma3 trials

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Unknown status·SSun Yat-sen University·Phase 3·NCT02362165·236 enrolled

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Terminated·SSherif Farag, MB, BS·Phase 1/2·NCT01177683·32 enrolled

Newly Diagnosed3 trials

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Recruiting·OOu Bai, MD/PHD·Phase 2·NCT07493148·50 enrolled

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Active, not recruiting· Incyte logo

Incyte·Phase 3·NCT04824092·899 enrolled

Brentuximab for Newly Diagnosed Hodgkin Disease

Completed·MMitchell Cairo·Phase 2·NCT02398240·40 enrolled

Stem Cell Transplant2 trials

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00051311·62 enrolled

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00074490·442 enrolled

Neoadjuvant Chemotherapy2 trials

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Recruiting·IInstitut Bergonié·Phase 2·NCT04968106·66 enrolled

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Unknown status·JJilin University·Phase 2·NCT02953184·160 enrolled

Leiomyosarcoma2 trials

Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT02997358·150 enrolled

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07125183·20 enrolled

Solid Tumors2 trials

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

Completed·AAGC Biologics S.p.A.·Phase 1·NCT00305084·15 enrolled

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Recruiting·GGeorgetown University·Phase 1·NCT05661201·24 enrolled

Hematologic Malignancies2 trials

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02419755·12 enrolled

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting·—·Phase 1·NCT05292664·30 enrolled

Ovarian Cancer2 trials

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Completed·AAGC Biologics S.p.A.·Phase 2·NCT03804866·14 enrolled

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06394492·440 enrolled

Induction Chemotherapy2 trials

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Completed·—·Phase 1·NCT01523977·22 enrolled

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Hepatocellular Carcinoma2 trials

Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial

Unknown status·PPD Dr. med. Matthias Dollinger·Phase 2·NCT01272557·170 enrolled

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Terminated·TTularik·Phase 2/3·NCT00057382·750 enrolled

Lenalidomide2 trials

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04423926·91 enrolled

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04432714·81 enrolled

Leukemia2 trials

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00968253·24 enrolled

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00669877·56 enrolled

Gastric Cancer2 trials

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Not yet recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT07486310·30 enrolled

Adjuvant PIPAC in Gastric Cancer Patients

Completed·MMichael Bau Mortensen·Phase 1·NCT04047004·20 enrolled

Triple-Negative Breast Cancer2 trials

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT05872412·82 enrolled

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Withdrawn·UUniversity of Chicago·N/A·NCT02637375

Rhabdomyosarcoma2 trials

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled

Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT03111069

Solid Tumor1 trial

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Active, not recruiting· Eisai logo

Eisai·Phase 1/2·NCT04008797·301 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 3·NCT00131027·240 enrolled

Monotherapy1 trial

Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient

Unknown status·SShi-Ming Lin·Phase 2·NCT01858207·60 enrolled

Sorafenib1 trial

Study in Asia of the Combination of TACE With Sorafenib in HCC Patients

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 2·NCT00990860·36 enrolled

Bladder Cancer1 trial

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Completed·UUniversity of Washington·Phase 2·NCT04383743·17 enrolled

Advanced Stage1 trial

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Prostate Cancer1 trial

Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

Terminated·UUniversity of Kentucky·Phase 2·NCT00176293·2 enrolled

Brentuximab Vedotin1 trial

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Recruiting·CChildren's Cancer Group, China·Phase 2/3·NCT06563245·96 enrolled

Endometrial Cancer1 trial

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Recruiting·HHutchmed·Phase 3·NCT06584032·412 enrolled

Ewing's Sarcoma1 trial

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Pembrolizumab1 trial

Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma

Completed·WWake Forest University Health Sciences·Phase 2·NCT03056001·30 enrolled

Bone Sarcoma1 trial

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT03277924·197 enrolled

Dedifferentiated Liposarcoma1 trial

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2/3·NCT05218499·400 enrolled

Efficacy1 trial

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209222·360 enrolled

Blinatumomab1 trial

RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

Recruiting·CChen Suning·Phase 2·NCT06250959·124 enrolled

Histiocytosis1 trial

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Unknown status·—·Phase 3·NCT02631109·120 enrolled

Soft-tissue Sarcomas1 trial

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting·IInstitut Bergonié·Phase 3·NCT03805022·351 enrolled

Immunotherapy1 trial

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

Recruiting·UUniversity of Kansas Medical Center·Phase 2·NCT05645380·139 enrolled

T-cell acute lymphoblastic leukemia1 trial

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03384654·47 enrolled

Advanced or Metastatic Solid Tumors1 trial

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Recruiting·DDynamiCure Biotechnology·Phase 1·NCT05785754·320 enrolled

Urothelial Carcinoma1 trial

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Completed·—·Phase 2·NCT00808639·39 enrolled

Locally Advanced1 trial

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00609765·1 enrolled

Osteosarcoma1 trial

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00586846·40 enrolled

Advanced Cancer1 trial

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02377752·25 enrolled

Advanced Cancers1 trial

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00798252·111 enrolled

Children1 trial

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02677116·68 enrolled

Peritoneal Cancer1 trial

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00262990·829 enrolled

Advanced Solid Tumors1 trial

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT00960063·4 enrolled

TACE1 trial

TATE Versus TACE in Intermediate Stage HCC

Terminated·TTeclison Ltd.·Phase 2·NCT03145558·6 enrolled

Lung Cancer1 trial

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Completed·PPharmaMar·Phase 3·NCT02566993·613 enrolled

Cardiotoxicity1 trial

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Not yet recruiting·TTanta University·Phase 1/2·NCT07370506·36 enrolled

Solid Tumours1 trial

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

Recruiting·RRace Oncology Ltd·Phase 1·NCT06815575·53 enrolled

Other Solid Tumors1 trial

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT00479128·80 enrolled

Glioblastoma Multiforme1 trial

MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme

Completed·WWashington University School of Medicine·Phase 1·NCT01851733·37 enrolled

Small Cell Lung Carcinoma1 trial

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

Completed·AAGC Biologics S.p.A.·Phase 2·NCT00483509·28 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Efficacy and Safety1 trial

An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00796120·121 enrolled

Childhood Acute Lymphoblastic Leukemia1 trial

Treatment of Childhood Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00165087·491 enrolled

Unspecified2 trials

PAD. ICORG 05-01, V11

Completed·CCancer Trials Ireland·Phase 2·NCT00814541·53 enrolled

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Completed·FFondazione Italiana Linfomi - ETS·Phase 3·NCT03159897·500 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DOXORUBICIN HYDROCHLORIDE

NDA NDA050467

Dec 23, 1987

DOXORUBICIN HYDROCHLORIDE

NDA NDA050629

Nov 17, 1995

DOXIL (LIPOSOMAL)

NDA NDA050718

Sources

References

[1]
ClinicalTrials.gov — 681 trial records for Doxorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Adriamycin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Doxorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Doxorubicin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050718). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Alpha Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Adriamycin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Breast Cancer38 trials

Lymphoma34 trials

Acute Lymphoblastic Leukemia12 trials

Diffuse Large B-Cell Lymphoma11 trials

Soft Tissue Sarcoma10 trials

Doxorubicin6 trials

Follicular Lymphoma5 trials

Neuroblastoma4 trials

Mantle Cell Lymphoma4 trials

Liver Cancer4 trials

Multiple Myeloma3 trials

Newly Diagnosed3 trials

Stem Cell Transplant2 trials

Neoadjuvant Chemotherapy2 trials

Leiomyosarcoma2 trials

Solid Tumors2 trials

Hematologic Malignancies2 trials

Ovarian Cancer2 trials

Induction Chemotherapy2 trials

Hepatocellular Carcinoma2 trials

Lenalidomide2 trials

Leukemia2 trials

Gastric Cancer2 trials

Triple-Negative Breast Cancer2 trials

Rhabdomyosarcoma2 trials

Solid Tumor1 trial

Adult Acute Lymphoblastic Leukemia1 trial

Monotherapy1 trial

Sorafenib1 trial

Bladder Cancer1 trial

Advanced Stage1 trial

Prostate Cancer1 trial

Brentuximab Vedotin1 trial

Endometrial Cancer1 trial

Ewing's Sarcoma1 trial

Pembrolizumab1 trial

Bone Sarcoma1 trial

Dedifferentiated Liposarcoma1 trial

Efficacy1 trial

Blinatumomab1 trial

Histiocytosis1 trial

Soft-tissue Sarcomas1 trial

Immunotherapy1 trial

T-cell acute lymphoblastic leukemia1 trial

Advanced or Metastatic Solid Tumors1 trial

Urothelial Carcinoma1 trial

Locally Advanced1 trial

Osteosarcoma1 trial

Advanced Cancer1 trial

Advanced Cancers1 trial

Children1 trial

Peritoneal Cancer1 trial

Advanced Solid Tumors1 trial

TACE1 trial

Lung Cancer1 trial

Cardiotoxicity1 trial

Solid Tumours1 trial

Other Solid Tumors1 trial

Glioblastoma Multiforme1 trial

Small Cell Lung Carcinoma1 trial

Real-world Study1 trial

Efficacy and Safety1 trial

Childhood Acute Lymphoblastic Leukemia1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News